Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business. During the third quarter, Edesa completed preparations for its Phase 2 […]
Read the full article on the original site.
Read Full Article